Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting

뉴스 본문을 불러오고 있어요.

Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting | 웨이프 WAPE

Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting

기사 요약

관련 종목

댓글 —